MSC – Med

MSC Med is a new interdisciplinary antenna from MSC lab (Matière et Systèmes Complexes, Université de Paris, CNRS UMR7057) dedicated to bioengineering and translational research. MSC-Med is located on Campus Saint Germain, 45 rue des Saints Pères (3rd floor) and affiliated to the UFR des sciences fondamentales et biomédicales, Faculté des Sciences.

MSC Med was created in 2018 to foster the merger of fundamental research, multidisciplinary training and entrepreneurship with the aim to promote biomedical innovation from bench to bedside. Our main goal is to envision and translate to the clinic novel diagnostic and therapeutic approaches based on nanomedicine, biotherapies and bioinspired technologies for precision medicine and personalized care.

Live/dead assay of fibroblasts on beads (from Léa Jabbour)

Schematic of an antero-cutaneous fistula (by Anna Sebbagh)

Co-culture of cholangiocarcinoma cells (GFP) and fibroblasts (mCherry) exposed to iron oxide nanoflowers decorated with gold NPs (by Sonia Becharef)

Schematic of an intestine affected by Crohn disease (by Anna Sebbagh)

Schematic of mesenchymal stem cells (by Anna Sebbagh)

Locomotion pattern of C. elegans (BPJ cover, JM Di Meglio)

Schematic of a mixed lymphocyte reaction assay (by Anna Sebbagh)


Schematic of an extracellular vesicle (by Anna Sebbagh)

Schematic of Atomic Force Microscopy (AFM) on polymers (by JM Di Meglio)

TEM on fibroblast exposed to Gold salts (by Giulio Avveduto).

Research topics in brief

We are interested in all the physical stimuli and cues (mechanical, magnetic, electric, optical, thermodynamical stimulation, exposure to nanoparticles…) that modulate or modify the behavior of human cells and tissues during development (embryogenesis), aging and pathogenesis (cancer, inflammation, nanotoxicology…). We are looking for disruptive biomimetic treatments for regenerative medicine and cancer therapy, based on cell-derived extracellular vesicles (EVs) and other bioactive nanotherapeutics. We believe on EVs as the next generation biotherapies and as a safer and affordable alternative to cell therapies. We are also very interested in studying the fate of nanoparticles and their potential in nanotherapies.

MSC-MED is pioneering breakthrough technologies for massive bioproduction, engineering and multimodal characterizations of extracellular vesicles and hybrid nanovectors, as well as fundamental understanding of the mechanisms of EV biogenesis and intercellular communication. MSC-MED launched in 2020, with the Region Ile de France and IDEX Université de Paris the first French EV facility and center of expertise (IVETh Core Facility) based on innovative and high-throughput bioproduction, analytical methods and data sciences to push EV-based therapy to the clinic. To this purpose, we launch a thematic group called EVOLVE.

MSC-Med hosts two spin-off companies: EVerZom created in 2019 to develop large-scale production and engineering of clinical grade EV and Evora Biosciences to translate EV-based therapy combined to a thermoresponsive hydrogel for fistula therapy.

We are a multidisciplinary group, gathering physicists, biologists, pharmacists, chemists, data scientist, engineers and entrepreneurs.

MSC Med and the IVETh facility benefits from the support of Université de Paris, IDEX UP, CNRS, INSERM, Region Ile de France, European Union (ERC, FET-Open), and several grant agencies and foundations (ANR, INCA, ANSES, ARC, VLM…).

We are constantly looking for highly motivated and highly skilled researcher and students. Do not hesitate to contact us.


Une étude d’ampleur sur l’effet des nanoparticules

Depuis quelques années, la chimie, la pharmacie, l’agriculture, l’agroalimentaire, les cosmétiques etc. se tournent de plus en plus vers des préparations contenant des nanoparticules. La présence croissante de ces nanoparticules dans notre environnement soulève des...

Financial supports